Evoke's Nasal Spray Meets Primary Endpoint In Safety Study

(RTTNews) - Evoke Pharma, Inc. (EVOK) Tuesday said its product EVK-001, a nasal spray for relieving the symptoms of partial stomach paralysis in women with diabetes, satisfied the primary endpoint of a study conducted to support a safety requirement for a new drug application.

The study found that the metoclopramide nasal spray did not prolong cardiac QT and corrected QT, Evoke Pharma said in a news release. Prolongation of the QT interval may heighten the risk of arrhythmia.

The double-blind TQT (Thorough QT) study tested 48 healthy male and female volunteers. Evoke used the antibiotic Moxifloxacin as a positive control.